Future Directions in the Management of Malignant Bone Tumors

  • Robert L. Souhami
Conference paper


In spite of the considerable improvements produced by combination chemotherapy, there remain many problems still to be tackled in order to enhance the survival rate of patients with primary malignant bone tumors. There is some evidence that current chemotherapy programs have reached a plateau in their effect on survival, and that further improvements are going to be difficult both to obtain and to detect. This chapter describes some of the remaining problems and discusses some possibilities for advancement. The increasing specialization of the treatment of primary malignant bone tumors has had the advantage that, in many countries, the expertise has been concentrated in a few major centers. This means that national and international collaboration in clinical trials should become easier if agreement can be reached on the nature of the questions to be posed.


Clin Oncol Pulmonary Metastasis Malignant Bone Tumor Round Cell Tumor Primary Malignant Bone Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Link MP, Goorin AM, Miser AW (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 134: 1600–1606CrossRefGoogle Scholar
  2. 2.
    Eiber F, Giuliano A, Eckardt J, et al. (1987) Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. J Clin Oncol 5: 21–26Google Scholar
  3. 3.
    Stiller CA, Bunch KJ (1990) Trends in survival for childhood cancer in Britain diagnosed 1971–85. Br J Cancer 62: 806–815PubMedCrossRefGoogle Scholar
  4. 4.
    Winkler K, Beron G, Kotz R (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study. J Clin Oncol 2: 617–624PubMedGoogle Scholar
  5. 5.
    Winkler K, Beron G, Delling G (1988) Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (Coss-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6: 329–337PubMedGoogle Scholar
  6. 6.
    Ryan J, Baker L, Benjamin R (1990) Long-term follow-up in the cure of osteogenic sarcoma. Chir Organi Mov 75 (Supp 1): 48PubMedGoogle Scholar
  7. 7.
    Ochs JJ, Freeman AI, Douglass HO (1978) Cis-dichlordiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62: 239–245PubMedGoogle Scholar
  8. 8.
    Taylor WF, Ivins JC, Unni K (1989) Prognostic variables in osteosarcoma: A multiinstitutional study. J Natl Cancer Inst 81: 21–30PubMedCrossRefGoogle Scholar
  9. 9.
    Bacci G, Picci P, Orlando M, et al. (1987) Prognostic value of serum alkaline phosphatase in osteosaracoma. Tumori 73: 331–336PubMedGoogle Scholar
  10. 10.
    Rosen G, Huvos AG, Marcove R, Nirenberg A (1986) Telangiectatic osteogenic sarcoma. Clin Orthop 207: 164–173PubMedGoogle Scholar
  11. 11.
    Sim FH, Unni KK, Beabout JW, Dahlin DC (1979) Osteosarcoma with small cells simulating Ewing’s tumor. J Bone Joint Surg [AM] 61A: 207–215.Google Scholar
  12. 12.
    Rosen G, Caparros B, Huvos AG (1982) Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221–1230PubMedCrossRefGoogle Scholar
  13. 13.
    Eckardt JJ, Eiber FR, Grant TT, et al. (1985) Management of stage IIB osteogenic sarcoma: Experience at the Unviersity of California, Los Angeles Cancer Treatment Symposia 3: 117–130Google Scholar
  14. 14.
    Jaffe N, Robertson R, Ayala A (1985) Comparison of intra-arterial cis-diamminedichloroplatinum II with high dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol 3: 1101–1110PubMedGoogle Scholar
  15. 15.
    Benjamin RS (1989) Regional chemotherapy for osteosarcoma. Semin Oncol 16: 323–327PubMedGoogle Scholar
  16. 16.
    Goorin AM, Delorey MJ, Lack EE, et al. (1984) Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: Analysis of 32 patients. J Clin Oncol 2: 425–431PubMedGoogle Scholar
  17. 17.
    Burgers JHV, Brair K, van Dobbenburgh AO, et al. (1980) Role of metastatectomy without chemotherapy in the management of osteosarcoma in children. Cancer 45: 1664–1668PubMedCrossRefGoogle Scholar
  18. 18.
    Han M-T, Telander RL, Pairolero PC, et al. (1981) Aggressive thoracotomy for pulmonary metastatic osteogenic sarcoma in children and young adolescents. J Ped Surg 16: 928–933CrossRefGoogle Scholar
  19. 19.
    Meyer WH, Schell MJ, Kumar APM (1987) Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival. Cancer 59: 374–379PubMedCrossRefGoogle Scholar
  20. 20.
    Sutow WW, Sullivan MP (1962) Cyclophosphamide therapy in children with Ewing’s sarcoma. Cancer Chemother Rep 23: 55–60PubMedGoogle Scholar
  21. 21.
    Selawry OS, Holland JF, Wolman IJ (1968) Effect of vincristine on malignant solid tumors in children. Cancer Chemother Rep 53: 497–500Google Scholar
  22. 22.
    Wang JJ, Cortes E, Sinks L, Holland JF (1971) Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer 28: 837–843PubMedCrossRefGoogle Scholar
  23. 23.
    Senyszyn JJ, Johnson RE, Curran RE (1970) Treatment of metastatic Ewing’s sarcoma with Actinomycin D (NSC-3053). Cancer Chemother Rep 54: 103–107PubMedGoogle Scholar
  24. 24.
    Oldham RK, Pomeroy TC (1972) Treatment of Ewing’s sarcoma with adriamycin (NSC-123127). Cancer Chemother Rep 56: 635–639PubMedGoogle Scholar
  25. 25.
    Magrath I, Sandlund J, Raynor A (1986) A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol 18 (Suppl 2): 25–28CrossRefGoogle Scholar
  26. 26.
    Hayes FA, Green A, Thompson E (1983) Phase II trial of VP 16–213 in pediatric solid tumors (Abstract No C-256). Proc Am Soc Cl in OncolGoogle Scholar
  27. 27.
    Nesbit ME, Perez CA, Tefft M (1981) Multimodal therapy for the management of primary non metastatic Ewing’s sarcoma of bone: An Intergroup Study. Nat Cancer Inst Monogr 56: 255–262PubMedGoogle Scholar
  28. 28.
    Nesbit ME, Gehan EA, Burgert EO (1990) Multimodal therapy for the management of primary, non-metastatic Ewing’s sarcoma of bone: A long-term follow-up of the first Intergroup study. J Clin Oncol 8: 1664–1674PubMedGoogle Scholar
  29. 29.
    Hayes FA, Thompson E, Meyer W, et al. (1989) Therapy for localized Ewing’s sarcoma of bone. J Clin Oncol 7: 208–213PubMedGoogle Scholar
  30. 30.
    Jürgens H, Exner U, Gadner H (1988) Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A 6-year experience of a European cooperative trial. Cancer 61: 23–32PubMedCrossRefGoogle Scholar
  31. 31.
    Bacci G, Picci P, Gherlinzoni F, et al. (1985) Localized Ewing’s sarcoma of bone: Ten years’ experience at the Instituto Orthopedico Rizzoli in 124 cases treated with multimodal therapy. Eur J Cancer Clin Oncol 21: 163–173PubMedCrossRefGoogle Scholar
  32. 32.
    Rosen G, Caparros B, Nirenberg A (1981) Ewing’s sarcoma: Ten-year experience with adjuvant chemotherapy. Cancer 47: 2204–2213PubMedCrossRefGoogle Scholar
  33. 33.
    Rosen G (1982) Current management of Ewing’s sarcoma. Progr Clin Cancer 8: 267–282Google Scholar
  34. 34.
    Kissane JM, Askin FB, Foulkes M, Strattan LB, Shirley SF (1983) Ewing’s sarcoma of bone: Clinico-pathological aspects of 303 cases from the Intergroup Ewing’s Sarcoma Study. Hum Path 14: 773–779PubMedCrossRefGoogle Scholar
  35. 35.
    Jaffe R, Santamaria M, Unis EJ (1984) The neuroectodermal tumor of bone. Am J Surg Pathol 8: 885–898PubMedCrossRefGoogle Scholar
  36. 36.
    Daugaard S, Kamby C, Sunde LM, et al. (1989) Ewing’s sarcoma: A retrospective study of histological and immunohistochemical factors and their relation to prognosis. Virchows Arch [A] 414: 243–251CrossRefGoogle Scholar
  37. 37.
    Hartman KR, Triche TJ, Kinsella TJ, Miser JS (1991) Prognostic value of histopathology in Ewing’s sarcoma. Long-term follow-up of distal extremity tumors. Cancer 67: 163–171PubMedCrossRefGoogle Scholar
  38. 38.
    Suit HD (1975) Role of therapeutic radiology in cancer of bone. Cancer 35: 930–935PubMedCrossRefGoogle Scholar
  39. 39.
    Newton WA, Meadows AT, Shimada H (1991) Bone sarcomas as second malignant neoplasms following childhood cancer. Cancer 67: 193–201PubMedCrossRefGoogle Scholar
  40. 40.
    Cangir A, Vietti TJ, Gehan EA, et al. (1990) Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two Intergroup Ewing’s sarcoma studies. Cancer 66: 887–893PubMedCrossRefGoogle Scholar
  41. 41.
    Earl HM (1987) Chemotherapy of rare malignant bone tumours. In: Souhami RL (ed) Bone Tumours. Ballières Clinical Oncology, vol 1. Ballières Tindall, London, pp 223–241Google Scholar
  42. 42.
    den Heeten GJ, Schraffordt-Koops H, Kamps WA, et al. (1985) Treatment of malignant fibrous histiocytoma of bone. A plea for primary chemotherapy. Cancer 56: 37–40CrossRefGoogle Scholar
  43. 43.
    Urban C, Rose C, Huvos AG (1983) Chemotherapy of malignant fibrous histiocytoma of bone. A report of five cases. Cancer 51: 795–802PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1992

Authors and Affiliations

  • Robert L. Souhami
    • 1
  1. 1.Department of OncologyUniversity College and Middlesex School of MedicineLondonUK

Personalised recommendations